Single Dose Pharmacokinetics of α-Dihydroergocryptine in Patients with Moderate to Severe Renal Insufficiency

Arzneimittel-Forschung/Drug Research

Volumn 53, Issue 11, 2003, Pages 769-773

  De Mey, Christian ^a   Sułowicz, Władyslaw ^b   Stompór, Tomasz ^b   Ezan, Eric ^c   Retzow, Angelika ^d   Althaus, Michael ^e  

^a ACPS   (Germany)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c DIF   (France)

^d Desitin Arzneimittel GmbH ^*

^e ALK SCHERAX Arzneimittel GmbH   (Germany)

Author keywords

Almirid ; CAS 14271 05 7; Dopamine agonist; Renal insufficiency; Dihydroergocryptine, clinical pharmacokinetics

Indexed keywords

CREATININE; DIHYDROERGOCRYPTINE; DRUG METABOLITE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EXCRETION; DRUG URINE LEVEL; ENZYME IMMUNOASSAY; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; OPEN STUDY; RADIOIMMUNOASSAY; SINGLE DRUG DOSE; URINARY EXCRETION;

EID: 0344010509     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1299827     Document Type: Article

References (15)

1. Battistin, L., Bardin, P. G., Ferro-Milone, F. et al., Alpha-dihydroergocryptine in Parkinson's disease: a multicentre randomized double blind parallel group study. Acta Neurol. Scand. 99, 36 (1999)
2. Bergamasco, B., Frattola, L., Muratorio, A. et al. Alpha- dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double blind, placebo-controlled study. Acta Neurol. Scand. 101, 372 (2000)
3. Markstein, R., Dopamine receptor profile of co-dergocrine (Hydergine®) and its components. Eur. J. Pharmacol. 86, 145 (1983)
4. Markstein, R., Glosse, A., Frick, W., Interaction of ergot alkaloids and their combination (co-dergocrine) with α-adrenoceptors in the CNS. Eur. J. Pharmacol. 93, 159 (1983)
5. Soskic, V., Petrovic, I., Effects of several ergosines on adenylate cyclase activity in synaptosomal membranes of the bovine caudate nucleus. J. Pharm. Pharmacol. 38, 128 (1986)
6. Zanotti, A., Coppi, G., Mailland, F., in: Progress in Gynecology and Obstetrics, A. R. Genazzani, F. Petraglia, A. Volpe (eds.), pp. 491-499. The Parthenon Publishing Group, Carnforth, UK (1990)
7. Mas-Chamberlin, C., Bromet, N., Olgiati, V. et al., Metabolism study of dihydro-α-ergocryptine,9,10-[9,10-3H(N)] in rat and human hepatocyte cultures and rat, monkey, and human microsomes. Am. J. Ther. 4, 291 (1997)
8. 3H-α-dihydroergocryptine mesylate. Am. J. Ther. 3, 553 (1996)
9. Althaus, M., Retzow, A., Castell, J. V., In vitro identification of the cytochrome P450 isoform responsible for the metabolism of α- dihydroergocryptine. Xenobiotica 30, 1033 (2000)
10. Collignon, F., Pradelles, P., Highly sensitive and specific radioimmunoassays for dihydroergotoxine components in plasma. Eur. J. Nucl. Med. 9, 23 (1984)
11. Ezan, E., Ardouin, T., Delhotal Landes, B. et al., Bioequivalence study of α-dihydroergocryptine: utility of metabolite evaluation. Int. J. Clin. Pharmacol. Ther. 34, 32 (1996)
12. Shah, V. P., Midha, K. K., Dighe, S. et al., Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Eur. J. Drug Metab. Pharmacokinet. 16, 249 (1991)
13. Kirch, W., Nokhodian, A., Halabi, A. et al., Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function. Eur. J. Drug Metab. Pharmacokinet. 17, 33 (1992)
14. Lavène, D., Humbert, H., Kiechel, J. R., et al. Pharmacocinétique de l'Hydergine® chez le sujet agé. J. Pharmacol. 16 (Suppl. III), 153 (1985)
15. Schneider, E., Alpha-Dihydroergocryptine - Pharmakologie und klinische Effekte. In: Morbus Parkinson: α-dihydroergocryptin - ein neuer Dopamin-Agonist, G. Deuschl (ed.), pp. 17-42, Thieme, Stuttgart-New York (1995)